

Best Vascular, a TeamBest Global Company, Celebrates 18 Year Anniversary of Serving the Cardiology Community

WASHINGTON, DC, USA, April 5, 2024 /EINPresswire.com/ -- Best Vascular/Novoste celebrates its 18th anniversary since Best Vascular acquired Novoste on March 9th 2006. Dr. [Krishnan Suthanthiran](#) and Best Medical International (BMI), one of the [TeamBest Global Companies](#), have been in Vascular Brachytherapy (VBT) for over 30 years. Starting in 1992, BMI engaged in pre-clinical research in animals with Dr. Ron Waksman of Washington Hospital Center in Washington, D.C. (at Emory University until 1997), and Dr. Ian Crocker at Emory University in Atlanta, Georgia and also starting in 1994, carried out Phase I Human Clinical Trials with Dr. Paul Teirstein, Dr. Vince Mazzoula, and Dr. Shires Jani of Scripps Clinic, La Jolla, California.

Novoste was established in 1995 and became a public company soon thereafter. In January 1996, at the very first Vascular Brachytherapy Conference in Atlanta, Georgia, with encouragement from Dr. Ron Waksman and Dr. Ian Crocker, BMI tried to work with Novoste and again in early 2004, but had little success in working with the Novoste management in place at that time.

Novoste assets were purchased by BMI in March 2006 as Novoste was planning to close down the Vascular Therapy operation.



www.teambest.com



www.bestvascular.com

VBT was approved for clinical use by US FDA on November 3, 2000. BMI continues to support and expand the use of VBT and is currently involved in developing new technologies.

Now, Best Vascular/Novoste—the only company to continue to support and promote Vascular Brachytherapy—is expanding in the coming years with new technologies and clinical trials.

Best Vascular/Novoste is eternally grateful to Dr. Ron Waksman, Dr. Paul Tierstein, Dr. Ian Crocker, Dr. Vince Mazzoula, and Dr. Shires Jani for the inventions and promotion of Vascular Brachytherapy.

Best Vascular/Novoste will be exhibiting at American College of Cardiology conference in Atlanta, GA from April 6-8, 2024. Please visit us at booths 3005, 3104 and 3107.

In addition to VBT products, BMI will be exhibiting self-shielded Cyclotron for producing a range of radioisotopes for cardiology, neurology, and oncology applications, as well as state-of-the-art high-resolution ultrasound for cardiology applications.

FROM MARCH 2006 PRESS RELEASE:

NORCROSS, GA. -(BUSINESS WIRE)- March 9, 2006 - Novoste Corporation (NASDAQ: NOVT) and Best Vascular, Inc. (Best Vascular) jointly announced today the completion of the sale of substantially all of the assets of Novoste's Vascular Brachytherapy (VBT) business to Best Vascular. The two companies had previously announced the transaction on October 12, 2005, and the Novoste shareholders' meeting at which the proposal to approve the transaction was adopted was held on March 7, 2006. The consideration for the sale of the assets by Novoste to Best Vascular was the assumption by Best Vascular of various liabilities of Novoste related to its VBT business. As part of the transaction, Novoste amended its charter to change its corporate name to "NOVT Corporation".



Best Cure Foundation — www.bestcure.md



www.teambest.com

Krish Suthanthiran, President of Best Vascular, has commented, "We are very excited about the opportunity that exists for Best Vascular in the VBT market. The acquisition of these assets fits our strategy of providing brachytherapy products across a wide variety of clinical applications. It is of utmost importance that radiation therapy is available to cardiologists and their patients. The Novoste system is the only remaining vascular brachytherapy product on the market and having previously supplied Cordis Corporation, a Johnson & Johnson company with VBT products, we believe we have the capability to assure the continuation of this important therapy in the cardiology market. We remain committed to our radiation oncology customer base and look forward to serving the particular needs of the cardiology community with a therapy that has proven to have durable results..."



Krishnan Suthanthiran, President & Founder of TeamBest Companies & Best Cure Foundation

Al Novak, President and Chief Executive Officer of Novoste, said "We are pleased that we have completed this transaction with Best Vascular. They have the capability and interest in supplying VBT to those physicians and their patients who have a need for this technology. This transaction was in the best interests of our shareholders by allowing Novoste to be free of its major liabilities associated with the VBT business."

Best Vascular, an affiliate of Best Medical International (BMI), was established for the purpose of focusing on the vascular brachytherapy business acquired from Novoste. BMI is known for its radiation seed products utilizing several different isotopes. BMI also has a complete line of catheters, needles, templates and accessories, including custom-designed products. Founded in 1977, BMI has pioneered new ideas in brachytherapy, including vascular brachytherapy, and is a leader in the provision of radiation seeds for use by urologists in the treatment of prostate cancer. BMI prides itself not only on its very successful product line, but also the ability of its staff to provide superlative service to its customers. BMI's mission is to uphold its excellent reputation by consistently exceeding the expectation of those it serves in the healthcare field by developing, manufacturing and delivering cost-effective, high quality products to benefit patients throughout the world.

For more information about Krishnan Suthanthiran, please visit his bio page at

http://www.teambest.com/about_bio.html.

For more information about Krishnan Suthanthiran's presentation on Rethinking Medicine, please visit

http://www.teambest.com/news/Rethinking_Medicine_Global_Healthcare_TX_Oct19_2022_presentation.pdf.

About TeamBest Global Companies:

TeamBest is a multinational medical company founded in 1977 in Springfield, Virginia, USA. TeamBest is driven by one primary goal—to provide the best products and services to customers.

The TeamBest family of companies, collectively known as TeamBest Global, has been proudly developing, manufacturing, and delivering reliable medical equipment and supplies for more than 40 years. TeamBest includes over a dozen companies offering complementary products and services for brachytherapy, health physics, medical physics, radiation therapy, blood irradiation, vascular brachytherapy, imaging, medical particle acceleration, cyclotrons, and proton-to-carbon heavy ion therapy systems. TeamBest is the single source for an expansive line of life-saving medical equipment and supplies. Its trusted team is constantly expanding and innovating to provide the most reliable products and technologies.

Today, TeamBest employs hundreds of talented engineers, scientists and others, offering thousands of products and services. TeamBest's independently-owned companies are proud to be represented in North America, Europe, Latin America, Africa, the Middle East, and Asia.

"Everyone deserves the Best healthcare. We aim to work with medical professionals to provide the Best products, technologies, and services. Our mission is to uphold our reputation for excellence in the healthcare field by developing, manufacturing and delivering cost-effective, high-quality products to benefit patients worldwide," states Krishnan Suthanthiran.

Krishnan Suthanthiran - President & Founder
TeamBest Global Companies & Best Cure Foundation
+1 703-451-2378
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/695032137>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.